# A Study to Determine if BHV-1400 is Effective and Safe in Adults With IgA Nephropathy

Study · id `cardio:ct-nct07642050` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07642050](<https://clinicaltrials.gov/study/NCT07642050>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07642050

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 420 participants.

## Technical summary

Registry record NCT07642050. Randomized; quadruple masking; primary purpose treatment. Start 2026-06 (anticipated); primary completion 2028-09 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 420 participants (planned count; ClinicalTrials.gov record NCT07642050, source copy `cardio:ctgov-nct07642050-2026-06-11`, retrieved 2026-10-26)
- Planned start: 2026-06 (anticipated) (ClinicalTrials.gov record NCT07642050, source copy `cardio:ctgov-nct07642050-2026-06-11`, retrieved 2026-10-26)
- Primary completion: 2028-09 (anticipated) (ClinicalTrials.gov record NCT07642050, source copy `cardio:ctgov-nct07642050-2026-06-11`, retrieved 2026-10-26)
- Completion: 2029-10 (anticipated) (ClinicalTrials.gov record NCT07642050, source copy `cardio:ctgov-nct07642050-2026-06-11`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07642050-2026-06-11`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study to Determine if BHV-1400 is Effective and Safe in Adults With IgA Nephropathy
- Condition: IgA Nephropathy
- Intervention (Drug): BHV-1400
- Intervention (Drug): Placebo
- Lead sponsor: Biohaven Therapeutics Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)

## Provenance

Content hash: 187f55e9e2af023f88b585ca317b8ffc4cdea7f3d52f2caa40fa291fd5c7c545
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
